Screener / SEC EDGAR /CIK 0001368514 /10-K filed Feb 25, 2026, compared with Mar 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Adma Biologics, Inc. ADMA

Compare with peers Embed
Planned sales, announced before they happen

1 trading plan running, 4 Form 144 notices for $6.3M

10-Q, 10-K and Form 144

What ADMA's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Dec 5, 2024 to Dec 31, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Adam Grossman
President and CEO
Adopted 10b5-1 plan Nov 14, 2025 10-K Feb 25, 2026
What the company wrote
During the quarter ended December 31, 2025, none of our directors or executive officers adopted or terminated any such contract, instruction or written plans except for Adam Grossman, our President and CEO, who entered into a Rule 10b5-1 trading plan with Fidelity Brokerage Services LLC on November 14, 2025 (the “Grossman Plan”). The Grossman Plan provides that Mr. Grossman may sell up to an aggregate of (i) 66,000 shares of our common stock and (ii) 165,000 shares of our common stock to be received upon the exercise of vested options granted to Mr. Grossman. The Grossman Plan is scheduled to terminate on December 31, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Grossman or the broker, or as otherwise provided in the plan.
Adam Grossman
President and CEO
Adopted 10b5-1 plan Dec 5, 2024 10-K Mar 18, 2025
What the company wrote
During the quarter ended December 31, 2024, none of our directors or executive officers adopted or terminated any such contract, instruction or written plans except for Adam Grossman, our President and CEO, who entered into a Rule 105b-1 trading plan with Fidelity Brokerage Services LLC on December 5, 2024 (the “Grossman Plan”). The Grossman Plan provides that Mr. Grossman may sell up to an aggregate of (i) 60,000 shares of our common stock and (ii) 150,000 shares of our common stock to be received upon the exercise of vested options granted to Mr. Grossman. The Grossman Plan is scheduled to terminate on December 31, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Grossman or the broker, or as otherwise provided in the plan.

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 10, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 5, 2026 Grossman Adam S.
Director, Officer
189,000 $2.0M
Mar 10, 2026 Tade Brad L.
Former Officer
50,026 $791K
Mar 9, 2026 Kestenberg-Messina Kaitlin M.
Officer
10,096 $155K
Feb 17, 2026 Grossman Adam S.
Director, Officer
209,000 $3.4M

From the Form 144 XML filed with the SEC, since Feb 17, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.